Actos (Pioglitazone) FDA Approval History

Original FDA Approval: July 1999

The FDA granted approval to pioglitazone hydrochloride on July 15, 1999 under NDA 021073, making it the second thiazolidinedione to reach the U.S. market after troglitazone (Rezulin). Takeda Pharmaceuticals developed the drug as a PPARγ agonist that improves insulin sensitivity in muscle, adipose tissue, and liver.

The approval rested on clinical trial data showing meaningful reductions in HbA1c. In key trials submitted to the FDA, pioglitazone 45 mg reduced HbA1c by 1.0 to 1.6 percentage points compared with placebo across monotherapy and combination regimens [1]. The drug was approved as monotherapy and in combination with sulfonylureas, metformin, or insulin for adults with type 2 diabetes who had inadequate glycemic control on diet and exercise alone.

Pioglitazone arrived at a critical moment. Troglitazone had already drawn FDA scrutiny for hepatotoxicity, and the agency pulled it from the market in March 2000, just eight months after pioglitazone's approval [2]. The removal of troglitazone left pioglitazone and rosiglitazone as the only available TZDs. This context shaped the FDA's close post-marketing surveillance of the entire class for years to come.

The PROactive Cardiovascular Outcomes Trial

PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events) remains the largest cardiovascular outcomes trial for any TZD. Published in The Lancet in 2005, it enrolled 5,238 patients with type 2 diabetes and pre-existing macrovascular disease, randomizing them to pioglitazone 45 mg or placebo over a mean follow-up of 34.5 months [3].

The primary composite endpoint (all-cause mortality, nonfatal MI, stroke, ACS, leg amputation, coronary revascularization, and leg revascularization) did not reach statistical significance (HR 0.90 to 95% CI 0.80 to 1.02, P=0.095). The pre-specified main secondary endpoint of death, MI, and stroke did reach significance (HR 0.84, P=0.027) [3]. Heart failure hospitalizations increased in the pioglitazone arm. Sixteen percent of pioglitazone patients experienced edema versus 8% on placebo.

PROactive produced a complicated regulatory picture. The secondary endpoint suggested cardiovascular benefit, but the primary endpoint miss and the heart failure signal gave the FDA reason for both encouragement and caution. This tension directly informed the 2007 label revision.

Black Box Warning for Heart Failure (2007)

In August 2007, the FDA mandated a black box warning on the pioglitazone label for congestive heart failure. The warning applies to the entire TZD class. It states that thiazolidinediones cause or worsen heart failure in some patients.

The label now contraindicates pioglitazone in patients with NYHA Class III or IV heart failure. Prescribers must monitor for signs of fluid retention, weight gain, and dyspnea. The mechanism involves PPARγ-mediated sodium and water retention in the renal collecting duct, a pharmacologic effect distinct from direct cardiac toxicity [4].

This was not pioglitazone's first safety-related label change. The FDA had already required warnings about edema and weight gain. But the black box represented the most serious regulatory action short of market withdrawal. The timing coincided with the rosiglitazone cardiovascular controversy, which culminated in the 2007 Nissen meta-analysis suggesting increased MI risk with that drug [5]. Pioglitazone's PROactive data, by contrast, suggested a neutral-to-favorable cardiovascular profile, which kept it on the market while rosiglitazone faced severe prescribing restrictions.

Bladder Cancer Signal and FDA Review (2010 to 2016)

In September 2010, the FDA issued an early communication about a potential association between pioglitazone and bladder cancer, based on interim results from a 10-year epidemiologic study Takeda had committed to conducting as a post-marketing requirement.

The timeline of FDA actions on this issue was dense. A June 2011 safety communication updated the findings: patients who used pioglitazone for more than 12 months had a statistically significant 40% increased risk of bladder cancer compared with those never exposed [6]. France and Germany suspended pioglitazone sales in 2011. The FDA did not follow suit but required a Medication Guide and label updates warning about the bladder cancer risk.

The completed 10-year Kaiser Permanente Northern California study (N=193,099) was published in 2015. It found no statistically significant increase in bladder cancer risk with ever-use of pioglitazone (HR 1.06 to 95% CI 0.89 to 1.26) [7]. Duration-response analyses showed a modest, non-significant elevation with use exceeding five years.

In December 2016, the FDA issued an updated safety review concluding that the data did not establish a definitive causal relationship between pioglitazone and bladder cancer. The agency retained the warning on the label but noted that the available studies gave inconsistent results. This ended six years of active review.

Pioglitazone for NASH: The PIVENS Trial and Off-Label Expansion

While pioglitazone's FDA-approved indication remains type 2 diabetes, the drug gained significant clinical traction for nonalcoholic steatohepatitis (NASH). The PIVENS trial (Pioglitazone versus Vitamin E versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis), published in the New England Journal of Medicine in 2010, randomized 247 adults without diabetes to pioglitazone 30 mg, vitamin E 800 IU, or placebo for 96 weeks [8].

Pioglitazone did not meet the pre-specified primary endpoint of improvement in the overall NASH histologic score (34% vs. 19% placebo, P=0.04, but the threshold was set at P<0.025 for each comparison). It did produce significant improvements in hepatic steatosis, lobular inflammation, and insulin resistance [8]. The AASLD practice guidance now lists pioglitazone as a pharmacotherapy option for biopsy-confirmed NASH, including in patients without diabetes, with a note that long-term benefits and risks must be weighed [9].

This off-label use represents a meaningful chapter in pioglitazone's regulatory story. The drug has never received an FDA indication for NASH or MASLD, and Takeda has not pursued one. Generic availability since 2012 removed much of the commercial incentive for a new indication filing. As a result, the AASLD guideline recommendation rests on academic evidence rather than a formal regulatory submission.

Generic Entry and Combination Products

Pioglitazone's composition-of-matter patent expired in 2012. The first generic versions received FDA approval in August 2012, and multiple manufacturers now produce the drug. Average wholesale price for generic pioglitazone 30 mg dropped below $0.50 per tablet, compared with peak branded Actos pricing above $10 per tablet.

The FDA also approved several fixed-dose combinations containing pioglitazone:

• Actoplus Met (pioglitazone/metformin): Approved 2005, available as immediate-release and extended-release formulations.
• Duetact (pioglitazone/glimepiride): Approved 2006.
• Oseni (pioglitazone/alogliptin): Approved 2013, combining a TZD with a DPP-4 inhibitor.

Each combination product carries the same black box warning for heart failure. Generic versions of Actoplus Met are available. Oseni remains branded under Takeda.

Current Label Status and Prescribing Considerations

The current pioglitazone prescribing information reflects the cumulative regulatory history described above. Key label elements include the black box warning for CHF, contraindication in NYHA Class III/IV heart failure, warnings for bladder cancer, bone fractures in females, macular edema, and ovulation induction in premenopausal anovulatory women.

The fracture risk warning, added in 2007, stemmed from data showing increased incidence of distal limb fractures in women taking pioglitazone. In a pooled analysis of clinical trials, fracture incidence was 2.6% in women on pioglitazone versus 1.7% on comparator drugs [10]. The mechanism involves PPARγ-mediated suppression of osteoblast differentiation, which shifts mesenchymal stem cell fate toward adipogenesis rather than bone formation.

The Endocrine Society's 2022 clinical practice guideline on pharmacologic management of type 2 diabetes positions pioglitazone as a second- or third-line agent, particularly when insulin resistance predominates and cost is a consideration [11]. The ADA Standards of Care list TZDs among oral options with high glucose-lowering efficacy (HbA1c reduction of 1.0 to 1.5 percentage points) and potential cardiovascular benefit, balanced against risks of weight gain, edema, fractures, and heart failure.

Post-Marketing Surveillance: Ongoing Pharmacovigilance

FDA Adverse Event Reporting System (FAERS) data continue to accrue for pioglitazone. The drug has been on the market for over 27 years. Recent pharmacovigilance reviews have not triggered new regulatory actions, but the FDA maintains pioglitazone on its active surveillance list.

A 2019 meta-analysis of 16 randomized controlled trials (N=3,813) examining pioglitazone in patients with insulin resistance and high cardiovascular risk found a 23% reduction in recurrent stroke or MI (HR 0.77 to 95% CI 0.64 to 0.93) [12]. The IRIS trial (Insulin Resistance Intervention after Stroke), published in the New England Journal of Medicine in 2016, showed that pioglitazone 45 mg reduced the composite of fatal or nonfatal stroke or MI by 24% in non-diabetic patients with insulin resistance who had experienced a recent ischemic stroke (HR 0.76 to 95% CI 0.62 to 0.93, P=0.007) [13].

These data have renewed interest in pioglitazone's cardiovascular and cerebrovascular protective effects but have not led to new FDA indications. The drug's regulatory profile remains defined by its 1999 diabetes approval and the subsequent safety-driven label revisions.

The American Heart Association and American Stroke Association included pioglitazone in their 2021 guidelines for secondary stroke prevention, recommending it as a consideration for patients with insulin resistance or prediabetes after ischemic stroke or TIA [14]. Pioglitazone 45 mg in the IRIS trial reduced new-onset diabetes by 52% (HR 0.48 to 95% CI 0.33 to 0.69) over 4.8 years of follow-up.